資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34392
|
| 標題: | Erythropoietin Use and the Risk of Stroke in Patients on Hemodialysis: A Retrospective Cohort Study in Taiwan |
| 作者: | Hung, Peir-Haur
Yeh, Chih-Ching
Hsiao, Chih-Yen
Muo, Chih-Hsin
Hung, Kuan-Yu
Tsai, Kuen-Jer |
| 貢獻者: | Chiayi Christian Hosp, Dept Internal Med, Ditmanson Med Fdn
Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth
Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth
China Med Univ, Dept Publ Hlth
Taipei Med Univ, Wan Fang Hosp, Canc Ctr
Taipei Med Univ, Coll Publ Hlth, Master Program Appl Mol Epidemiol
Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
China Med Univ Hosp, Management Off Hlth Data
Natl Taiwan Univ Hosp, Dept Internal Med
Natl Cheng Kung Univ, Coll Med, Inst Clin Med
Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Ctr Clin Med |
| 關鍵字: | end-stage renal disease
erythropoietin
hemodialysis
ischemic stroke |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:49:19 (UTC+8) |
| 出版者: | WILEY |
| 摘要: | Background Targeting higher hemoglobin levels with erythropoietin to treat anemia in patients with chronic kidney disease is associated with increased cardiovascular risk, including that of stroke. The risks of the subtypes of stroke, ischemic, hemorrhagic, and unspecified, following the administration of erythropoietin in patients with end-stage renal disease receiving hemodialysis remain unclear. Methods and results Overall, 12 948 adult patients with end-stage renal disease treated during 1999 to 2010 who had undergone hemodialysis were included. The study end points were the incidences of stroke and its subtypes. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) of stroke and its subtypes in erythropoietin recipients compared with nonrecipients. Patients in the erythropoietin cohort did not have an increased risk of stroke compared with those in the nonerythropoietin cohort (adjusted HR, 1.03; 95% CI, 0.92-1.15). Compared with patients in the nonerythropoietin cohort, the risks of ischemic, hemorrhagic, or unspecified stroke were not higher in patients in the erythropoietin cohort (adjusted HRs, 1.08 [95% CI, 0.93-1.26], 0.96 [95% CI, 0.78-1.18], and 1.03 [95% CI, 0.80-1.32], respectively). Increased risks of stroke and its subtypes were not observed with even large annual defined daily doses of erythropoietin (>201). Conclusions Erythropoietin in patients receiving hemodialysis is not associated with increased risk of stroke or any of its subtypes. |
| 關聯: | J AM HEART ASSOC, v.10, n.14 |
| 顯示於類別: | [生活保健科技系] 期刊論文
[醫務管理系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 256 | 檢視/開啟 | | JAHA.120.019529.pdf | | 469Kb | Adobe PDF | 56 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
